COVID-19 drug research and the cohort multiple randomised controlled trial design

Eur Respir J. 2022 Sep 15;60(3):2200746. doi: 10.1183/13993003.00746-2022. Print 2022 Sep.

Abstract

In the cohort multiple randomised controlled trial design, consent is not sought from control group participants in each trial conducted within the cohort, so it is ethically inappropriate for assessment of medicinal products in COVID-19 patients https://bit.ly/3xtBX3m

Trial registration: ClinicalTrials.gov NCT04324047.

Publication types

  • Letter
  • Comment

MeSH terms

  • Adult
  • COVID-19*
  • Critical Illness
  • Humans
  • Hydroxychloroquine / adverse effects
  • Receptors, Interleukin-6
  • SARS-CoV-2

Substances

  • Receptors, Interleukin-6
  • Hydroxychloroquine

Associated data

  • ClinicalTrials.gov/NCT04324047